News

The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…

Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…

The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…

Use of glucagon-like peptide-1 (GLP-1) receptor agonists in people with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) — forms of…

A 34-year-old woman with Alagille syndrome and vascular problems — who had been implanted with a stent for her narrowed pulmonary arteries — experienced…

The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy bemnifosbuvir and ruzasvir in adults with chronic…

The Scottish Medicines Consortium (SMC) has agreed that Ipsen’s Iqirvo (elafibranor) be covered by the country’s public National Health Service (NHS), making the therapy…

Severe mutations in the ABCB11 gene cause progressive familial intrahepatic cholestasis type 2 (PFIC2) by destabilizing the resulting BSEP protein in a specific region,…

Enrollment is complete for a Phase 3 clinical trial testing lanifibranor in people with metabolic dysfunction-associated steatohepatitis (MASH) — a severe type of fatty…

Measuring the blood levels of bile acids, the main component of the digestive fluid bile, can help predict key clinical outcomes for babies with…